GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » Cyclically Adjusted PS Ratio

Acorda Therapeutics (Acorda Therapeutics) Cyclically Adjusted PS Ratio : 0.00 (As of May. 03, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-05-03), Acorda Therapeutics's current share price is $0.85. Acorda Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $977.88. Acorda Therapeutics's Cyclically Adjusted PS Ratio for today is 0.00.

The historical rank and industry rank for Acorda Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

During the past years, Acorda Therapeutics's highest Cyclically Adjusted PS Ratio was 7.96. The lowest was 0.01. And the median was 1.21.

ACORQ's Cyclically Adjusted PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.17
* Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Acorda Therapeutics's adjusted revenue per share data for the three months ended in Dec. 2023 was $30.584. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $977.88 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Acorda Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Acorda Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Cyclically Adjusted PS Ratio Chart

Acorda Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.08 0.04 0.01 0.02

Acorda Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.02

Competitive Comparison of Acorda Therapeutics's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Cyclically Adjusted PS Ratio falls into.



Acorda Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Acorda Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.85/977.88
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acorda Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Acorda Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=30.584/129.4194*129.4194
=30.584

Current CPI (Dec. 2023) = 129.4194.

Acorda Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 228.744 99.695 296.946
201406 274.376 100.560 353.120
201409 300.173 100.428 386.827
201412 328.334 99.070 428.918
201503 285.289 99.621 370.624
201506 314.978 100.684 404.874
201509 409.390 100.392 527.764
201512 355.712 99.792 461.318
201603 310.735 100.470 400.269
201606 337.190 101.688 429.145
201609 358.765 101.861 455.829
201612 371.047 101.863 471.426
201703 312.529 102.862 393.218
201706 364.068 103.349 455.906
201709 368.316 104.136 457.742
201712 489.345 104.011 608.884
201803 273.621 105.290 336.329
201806 390.081 106.317 474.845
201809 363.394 106.507 441.571
201812 174.186 105.998 212.674
201903 111.457 107.251 134.495
201906 126.396 108.070 151.366
201909 120.510 108.329 143.971
201912 126.877 108.420 151.451
202003 70.601 108.902 83.903
202006 84.467 108.767 100.505
202009 38.332 109.815 45.175
202012 90.213 109.897 106.239
202103 60.890 111.754 70.515
202106 63.570 114.631 71.771
202109 56.474 115.734 63.152
202112 62.234 117.630 68.472
202203 33.988 121.301 36.263
202206 35.939 125.017 37.205
202209 27.025 125.227 27.930
202212 21.992 125.222 22.729
202303 18.289 127.348 18.587
202306 23.893 128.729 24.021
202309 22.315 129.860 22.239
202312 30.584 129.419 30.584

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Acorda Therapeutics  (OTCPK:ACORQ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Acorda Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics (Acorda Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Executives
Thomas M. Burns director 2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen officer: CEO and President C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser officer: Chief Financial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff officer: General Counsel 11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem officer: Chief Commercial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales officer: Interim PAO & PFO 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman officer: Exec V Pres, Gen Cnsl & Sec C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: Exec. VP-Commercial Dvlpmnt C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence officer: Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank officer: Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc. 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123

Acorda Therapeutics (Acorda Therapeutics) Headlines